CRISPR Therapeutics AG $CRSP Position Increased by Profund Advisors LLC

Profund Advisors LLC boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 42.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 41,562 shares of the company’s stock after purchasing an additional 12,479 shares during the period. Profund Advisors LLC’s holdings in CRISPR Therapeutics were worth $2,299,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Choreo LLC boosted its stake in shares of CRISPR Therapeutics by 3.4% during the third quarter. Choreo LLC now owns 7,539 shares of the company’s stock worth $417,000 after buying an additional 247 shares during the period. Interchange Capital Partners LLC increased its position in CRISPR Therapeutics by 6.0% in the 3rd quarter. Interchange Capital Partners LLC now owns 4,766 shares of the company’s stock valued at $264,000 after acquiring an additional 268 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in CRISPR Therapeutics by 14.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,643 shares of the company’s stock valued at $988,000 after acquiring an additional 2,293 shares during the last quarter. D.A. Davidson & CO. raised its stake in CRISPR Therapeutics by 17.0% during the 3rd quarter. D.A. Davidson & CO. now owns 7,398 shares of the company’s stock valued at $409,000 after acquiring an additional 1,074 shares during the last quarter. Finally, Oppenheimer & Co. Inc. lifted its position in CRISPR Therapeutics by 5.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 9,256 shares of the company’s stock worth $512,000 after acquiring an additional 457 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In related news, General Counsel James Kasinger sold 1,040 shares of the company’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $49.26, for a total value of $51,230.40. Following the sale, the general counsel owned 95,857 shares in the company, valued at $4,721,915.82. This represents a 1.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ali Behbahani sold 13,679 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $57.09, for a total value of $780,934.11. Following the completion of the transaction, the director directly owned 16,637 shares of the company’s stock, valued at $949,806.33. The trade was a 45.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 93,558 shares of company stock valued at $4,881,663 in the last 90 days. Insiders own 5.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $51.42 on Monday. The stock has a market capitalization of $4.97 billion, a price-to-earnings ratio of -10.80 and a beta of 1.76. CRISPR Therapeutics AG has a 52 week low of $44.12 and a 52 week high of $65.98. The firm has a 50-day moving average price of $54.19 and a 200 day moving average price of $52.92. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. The company had revenue of $10.18 million for the quarter. Equities research analysts anticipate that CRISPR Therapeutics AG will post -4.44 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on CRSP. Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Citizens Jmp restated a “market outperform” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a report on Monday, September 28th. William Blair upgraded shares of CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $65.75.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.